{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:12:25Z","timestamp":1792512745368,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40259-024-00653-6","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:02:10Z","timestamp":1710500530000},"page":"425-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database"],"prefix":"10.1007","volume":"38","author":[{"given":"Paola Maria","family":"Cutroneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Arzenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Furci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Scapini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bulzom\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Luxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Caminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-7296","authenticated-orcid":false,"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"2","key":"653_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373. https:\/\/doi.org\/10.1183\/09031936.00202013. (Erratum in: Eur Respir J. 2014 Apr;43(4):1216. Dosage error in article text. Erratum in: Eur Respir J. 2018 Jul 27;52(1): Erratum in: Eur Respir J. 2022 Jun 9;59(6)).","journal-title":"Eur Respir J"},{"issue":"4","key":"653_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100032","volume":"12","author":"A Vianello","year":"2019","unstructured":"Vianello A, Caminati M, Andretta M, Menti AM, Tognella S, Senna G, Degli EL. Prevalence of severe asthma according to the drug regulatory agency perspective: An Italian experience. World Allergy Organ J. 2019;12(4): 100032. https:\/\/doi.org\/10.1016\/j.waojou.2019.100032.","journal-title":"World Allergy Organ J"},{"issue":"12","key":"653_CR3","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1080\/03007995.2018.1505352","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075\u201388. https:\/\/doi.org\/10.1080\/03007995.2018.1505352.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"653_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12016-020-08776-8","volume":"59","author":"M Mavissakalian","year":"2020","unstructured":"Mavissakalian M, Brady S. The current state of biologic therapies for treatment of refractory asthma. Clin Rev Allergy Immunol. 2020;59(2):195\u2013207. https:\/\/doi.org\/10.1007\/s12016-020-08776-8.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"653_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00588-2019","volume":"55","author":"F Holguin","year":"2020","unstructured":"Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P, Tonia T, Adcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P, Custovic A, Djukanovic R, Frey U, Frankem\u00f6lle B, Gibson P, Hamerlijnck D, Jarjour N, Konno S, Shen H, Vitary C, Bush A. Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline. Eur Respir J. 2020;55(1): 1900588. https:\/\/doi.org\/10.1183\/13993003.00588-2019.","journal-title":"Eur Respir J"},{"issue":"7","key":"653_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/biomedicines9070760","volume":"9","author":"D Russo","year":"2021","unstructured":"Russo D, Di Filippo P, Attanasi M, Lizzi M, Di Pillo S, Chiarelli F. Biologic therapy and severe asthma in children. Biomedicines. 2021;9(7):760. https:\/\/doi.org\/10.3390\/biomedicines9070760.","journal-title":"Biomedicines."},{"key":"653_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107414","volume":"218","author":"L Rogers","year":"2023","unstructured":"Rogers L, Jesenak M, Bjermer L, Hanania NA, Seys SF, Diamant Z. Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023;218: 107414. https:\/\/doi.org\/10.1016\/j.rmed.2023.107414.","journal-title":"Respir Med"},{"issue":"10335","key":"653_CR8","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","volume":"399","author":"M Lommatzsch","year":"2022","unstructured":"Lommatzsch M, Brusselle GG, Canonica GW, Jackson DJ, Nair P, Buhl R, Virchow JC. Disease-modifying anti-asthmatic drugs. Lancet. 2022;399(10335):1664\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(22)00331-2.","journal-title":"Lancet"},{"issue":"4","key":"653_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789\u201398. https:\/\/doi.org\/10.1016\/j.chest.2016.03.032.","journal-title":"Chest"},{"issue":"5","key":"653_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O\u2019Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366. https:\/\/doi.org\/10.1016\/S2213-2600(15)00042-9. (Erratum in: Lancet Respir Med. 2015 Apr;3(4):e15. Erratum in: Lancet Respir Med. 2016 Oct;4(10 ):e50).","journal-title":"Lancet Respir Med"},{"issue":"9","key":"653_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","volume":"154","author":"NA Hanania","year":"2011","unstructured":"Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573\u201382. https:\/\/doi.org\/10.7326\/0003-4819-154-9-201105030-00002. (Erratum in: Ann Intern Med. 2019 Oct 1;171(7):528).","journal-title":"Ann Intern Med"},{"issue":"2","key":"653_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","volume":"108","author":"W Busse","year":"2001","unstructured":"Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184\u201390. https:\/\/doi.org\/10.1067\/mai.2001.117880.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"653_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1398-9995.2004.00533.x","volume":"59","author":"JG Ayres","year":"2004","unstructured":"Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59(7):701\u20138. https:\/\/doi.org\/10.1111\/j.1398-9995.2004.00533.x.","journal-title":"Allergy"},{"key":"653_CR14","doi-asserted-by":"publisher","unstructured":"Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568\u201376. https:\/\/doi.org\/10.1016\/S2213-2600(17)30190-X.","DOI":"10.1016\/S2213-2600(17)30190-X"},{"issue":"9","key":"653_CR15","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","volume":"38","author":"N Lugogo","year":"2016","unstructured":"Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058\u201320701. https:\/\/doi.org\/10.1016\/j.clinthera.2016.07.010.","journal-title":"Clin Ther"},{"issue":"26","key":"653_CR16","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"key":"653_CR17","unstructured":"Food and Drug Administration Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-approves-label-changes-asthma-drug-xolair-omalizumab-including. Accessed June 13, 2023."},{"key":"653_CR18","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Omalizumab: potential risk of arterial thrombotic events. https:\/\/www.gov.uk\/drug-safety-update\/omalizumab-potential-risk-of-arterial-thrombotic-events. Accessed June 13, 2023."},{"issue":"10","key":"653_CR19","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1111\/all.15008","volume":"76","author":"D Mota","year":"2021","unstructured":"Mota D, Rama TA, Severo M, Moreira A. Potential cancer risk with omalizumab? A disproportionality analysis of the WHO\u2019s VigiBase pharmacovigilance database. Allergy. 2021;76(10):3209\u201311. https:\/\/doi.org\/10.1111\/all.15008.","journal-title":"Allergy"},{"issue":"3","key":"653_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1590\/1806-9282.20221358","volume":"69","author":"J Baddini-Martinez","year":"2023","unstructured":"Baddini-Martinez J, Leit\u00e3o Filho FS, Caetano LSB. Anaphylactic risks associated with immunobiological agents in asthma therapy. Rev Assoc Med Bras. 2023;69(3):367\u20139. https:\/\/doi.org\/10.1590\/1806-9282.20221358.","journal-title":"Rev Assoc Med Bras"},{"issue":"4","key":"653_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","volume":"37","author":"PM Tregunno","year":"2014","unstructured":"Tregunno PM, Fink DB, Fernandez-Fernandez C, L\u00e1zaro-Bengoa E, Nor\u00e9n GN. Performance of probabilistic method to detect duplicate individual case safety reports. Drug Saf. 2014;37(4):249\u201358. https:\/\/doi.org\/10.1007\/s40264-014-0146-y.","journal-title":"Drug Saf"},{"key":"653_CR22","unstructured":"ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Glossary of ICH terms and definitions; 2023. https:\/\/cioms.ch\/publications\/product\/glossary-of-ich-terms-and-definitions. Accessed July 31, 2023."},{"key":"653_CR23","unstructured":"European Medicines Agency (EMA). Inclusion\/exclusion criteria for the \u201cImportant Medical Events\u201d list. https:\/\/www.ema.europa.eu\/en\/documents\/other\/inclusion-exclusion-criteria-important-medical-events-list-meddra_en.pdf Accessed July 31, 2023."},{"key":"653_CR24","unstructured":"Food and Drug Administration. FDA Online Label Repository. https:\/\/labels.fda.gov\/. Accessed June 21, 2023."},{"key":"653_CR25","unstructured":"European Medicines Agency (EMA). Medicines EPAR. https:\/\/www.ema.europa.eu\/en\/medicines\/field_ema_web_categories%253Aname_field\/Human\/ema_group_types\/ema_medicine. Accessed June 21, 2023."},{"issue":"6","key":"653_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"653_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AF Wisniewski","year":"2016","unstructured":"Wisniewski AF, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, Macia-Martinez MA, Manlik K, Quarcoo N, Seabroke S, Slattery J, Southworth H, Thakrar B, Tregunno P, Van Holle L, Kayser M, Nor\u00e9n GN. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469\u201390. https:\/\/doi.org\/10.1007\/s40264-016-0405-1.","journal-title":"Drug Saf"},{"issue":"6","key":"653_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, Wisniewski A, Slattery J. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577\u201387. https:\/\/doi.org\/10.1007\/s40264-015-0289-5.","journal-title":"Drug Saf"},{"key":"653_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jclinepi.2021.07.014","volume":"139","author":"C Khouri","year":"2021","unstructured":"Khouri C, Revol B, Lepelley M, Mouffak A, Bernardeau C, Salvo F, Pariente A, Roustit M, Cracowski JL. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. J Clin Epidemiol. 2021;139:191\u20138. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.07.014.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"653_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","volume":"32","author":"M Hauben","year":"2009","unstructured":"Hauben M, Aronson JK. Defining \u201csignal\u201d and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32(2):99\u2013110. https:\/\/doi.org\/10.2165\/00002018-200932020-00003.","journal-title":"Drug Saf"},{"key":"653_CR31","unstructured":"European Medicines Agency (EMA, 2017). Guideline on good pharmacovigilance practices (GVP)\u2014Module IX Addendum I\u2013 Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. EMA\/209012\/2015."},{"key":"653_CR32","unstructured":"Council for International Organizations of Medical Sciences, editor. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. Geneva: CIOMS; 2010."},{"key":"653_CR33","unstructured":"European Medicines Agency (EMA, 2016). EMA\/849944\/2016. Screening for adverse reactions in EudraVigilance. https:\/\/www.ema.europa.eu\/en\/documents\/ Accessed July 12, 2023."},{"issue":"5","key":"653_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","volume":"70","author":"B Grundmark","year":"2014","unstructured":"Grundmark B, Holmberg L, Garmo H, Zethelius B. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur J Clin Pharmacol. 2014;70(5):627\u201335. https:\/\/doi.org\/10.1007\/s00228-014-1658-1.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"653_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.15178","volume":"89","author":"W Alkabbani","year":"2023","unstructured":"Alkabbani W, Gamble JM. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors. Br J Clin Pharmacol. 2023;89(2):431\u20139. https:\/\/doi.org\/10.1111\/bcp.15178.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"653_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/joim.12991","volume":"288","author":"F Cohen Aubart","year":"2020","unstructured":"Cohen Aubart F, Lhote R, Amoura A, Valeyre D, Haroche J, Amoura Z, Lebrun-Vignes B. Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Intern Med. 2020;288(3):356\u201362. https:\/\/doi.org\/10.1111\/joim.12991.","journal-title":"J Intern Med"},{"issue":"2","key":"653_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jaad.2021.09.050","volume":"86","author":"T Bettuzzi","year":"2022","unstructured":"Bettuzzi T, Drucker A, Staumont-Sall\u00e9 D, Bihan K, Lebrun-Vignes B, Sbidian E. Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database. J Am Acad Dermatol. 2022;86(2):431\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2021.09.050.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"653_CR38","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.26355\/eurrev_202206_28977","volume":"26","author":"R Alroobaea","year":"2022","unstructured":"Alroobaea R, Rubaiee S, Hanbazazah AS, Jahrami H, Garbarino S, Damiani G, Wu J, Bragazzi NL. IL-4\/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization individual case safety reporting pharmacovigilance database (VigiBase\u2122): a big data and machine learning analysis. Eur Rev Med Pharmacol Sci. 2022;26(11):4074\u201381. https:\/\/doi.org\/10.26355\/eurrev_202206_28977.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"653_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12038","volume":"11","author":"L Li","year":"2021","unstructured":"Li L, Wang Z, Cui L, Xu Y, Guan K, Zhao B. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clin Transl Allergy. 2021;11(4): e12038. https:\/\/doi.org\/10.1002\/clt2.12038.","journal-title":"Clin Transl Allergy"},{"key":"653_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02573-3","author":"E Hirai","year":"2023","unstructured":"Hirai E, Haruki T, Baba T, Miyazaki D. Analyses of dupilumab-related ocular adverse drug reactions using the WHO\u2019s VigiBase. Adv Ther. 2023. https:\/\/doi.org\/10.1007\/s12325-023-02573-3.","journal-title":"Adv Ther"},{"issue":"3","key":"653_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","volume":"17","author":"H Fuseini","year":"2017","unstructured":"Fuseini H, Newcomb DC. Mechanisms driving gender differences in asthma. Curr Allergy Asthma Rep. 2017;17(3):19. https:\/\/doi.org\/10.1007\/s11882-017-0686-1.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"11","key":"653_CR42","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.rmed.2010.07.011","volume":"104","author":"P Chanez","year":"2010","unstructured":"Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, de Lara MT, Blanco P, Moreau JF, Robinson P, Bourdeix I, Trunet P, Le Gros V, Humbert M, Molimard M. Omalizumab-induced decrease of Fc\u03beRI expression in patients with severe allergic asthma. Respir Med. 2010;104(11):1608\u201317. https:\/\/doi.org\/10.1016\/j.rmed.2010.07.011.","journal-title":"Respir Med"},{"key":"653_CR43","doi-asserted-by":"publisher","unstructured":"Diamant Z, Vijverberg S, Alving K, Bakirtas A, Bjermer L, Custovic A, Dahlen SE, Gaga M, Gerth van Wijk R, Giacco SD, Hamelmann E, Heaney LG, Heffler E, Kalayci \u00d6, Kostikas K, Lutter R, Olin AC, Sergejeva S, Simpson A, Sterk PJ, Tufvesson E, Agache I, Seys SF. Toward clinically applicable biomarkers for asthma: an EAACI position paper. Allergy. 2019;74(10):1835\u201351. https:\/\/doi.org\/10.1111\/all.13806.","DOI":"10.1111\/all.13806"},{"key":"653_CR44","doi-asserted-by":"publisher","unstructured":"Roche N, Anzueto A, Bosnic Anticevich S, Kaplan A, Miravitlles M, Ryan D, Soriano JB, Usmani O, Papadopoulos NG, Canonica GW; Respiratory Effectiveness Group Collaborators. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. Eur Respir J. 2019;54(3):1901511. https:\/\/doi.org\/10.1183\/13993003.01511-2019.","DOI":"10.1183\/13993003.01511-2019"},{"issue":"4","key":"653_CR45","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","volume":"157","author":"E Wang","year":"2020","unstructured":"Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, Cho YS, Canonica GW, Heffler E, Gibson PG, Hew M, Peters M, Harvey ES, Alacqua M, Zangrilli J, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Hosseini N, Murray RB, Price DB. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157(4):790\u2013804. https:\/\/doi.org\/10.1016\/j.chest.2019.10.053. (Erratum in: Chest. 2021;160(5):1989).","journal-title":"Chest"},{"issue":"9","key":"653_CR46","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/1744666X.2019.1653758","volume":"15","author":"E Heffler","year":"2019","unstructured":"Heffler E, Paoletti G, Giorgis V, Puggioni F, Racca F, Del Giacco S, Bagnasco D, Caruso C, Brussino L, Rolla G, Canonica GW. Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Rev Clin Immunol. 2019;15(9):951\u20138. https:\/\/doi.org\/10.1080\/1744666X.2019.1653758.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"653_CR47","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","volume":"9","author":"K Eger","year":"2021","unstructured":"Eger K, Kroes JA, Ten Brinke A, Bel EH. Long-term therapy response to anti-il-5 biologics in severe asthma\u2014a real-life evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194\u2013200. https:\/\/doi.org\/10.1016\/j.jaip.2020.10.010.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"653_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","volume":"158","author":"JE Kavanagh","year":"2020","unstructured":"Kavanagh JE, d\u2019Ancona G, Elstad M, Green L, Fernandes M, Thomson L, Roxas C, Dhariwal J, Nanzer AM, Kent BD, Jackson DJ. Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491\u2013500. https:\/\/doi.org\/10.1016\/j.chest.2020.03.042.","journal-title":"Chest"},{"key":"653_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113978","volume":"179","author":"JA Kroes","year":"2020","unstructured":"Kroes JA, Zielhuis SW, van Roon EN, Ten Brinke A. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. Biochem Pharmacol. 2020;179: 113978. https:\/\/doi.org\/10.1016\/j.bcp.2020.113978.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"653_CR50","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00444-2022","volume":"9","author":"E Khaleva","year":"2023","unstructured":"Khaleva E, Rattu A, Brightling C, Bush A, Bourdin A, Bossios A, Chung KF, Chaudhuri R, Coleman C, Djukanovic R, Dahl\u00e9n SE, Exley A, Fleming L, Fowler SJ, Gupta A, Hamelmann E, Koppelman GH, Mel\u00e9n E, Mahler V, Seddon P, Singer F, Porsbjerg C, Ramiconi V, Rusconi F, Yasinska V, Roberts G. Definitions of non-response and response to biological therapy for severe asthma: a systematic review. ERJ Open Res. 2023;9(3): 00444-2022. https:\/\/doi.org\/10.1183\/23120541.00444-2022.","journal-title":"ERJ Open Res"},{"issue":"3","key":"653_CR51","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaip.2020.10.048","volume":"9","author":"AN Pepper","year":"2021","unstructured":"Pepper AN, Hanania NA, Humbert M, Casale TB. How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit. J Allergy Clin Immunol Pract. 2021;9(3):1081\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2020.10.048.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"653_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13601-020-00335-w","volume":"10","author":"D Ferastraoaru","year":"2020","unstructured":"Ferastraoaru D, Bax HJ, Bergmann C, Capron M, Castells M, Dombrowicz D, Fiebiger E, Gould HJ, Hartmann K, Jappe U, Jordakieva G, Josephs DH, Levi-Schaffer F, Mahler V, Poli A, Rosenstreich D, Roth-Walter F, Shamji M, Steveling-Klein EH, Turner MC, Untersmayr E, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clin Transl Allergy. 2020;10:32. https:\/\/doi.org\/10.1186\/s13601-020-00335-w.","journal-title":"Clin Transl Allergy"},{"issue":"3","key":"653_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1081-1206(10)60184-6","volume":"103","author":"AA Long","year":"2009","unstructured":"Long AA, Fish JE, Rahmaoui A, Miller MK, Bradley MS, Taki HN, Demeo AN, Tilles SA, Szefler SJ. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol. 2009;103(3):212\u20139. https:\/\/doi.org\/10.1016\/S1081-1206(10)60184-6.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"653_CR54","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","volume":"129","author":"W Busse","year":"2012","unstructured":"Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, Canvin J. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983-9.e6. https:\/\/doi.org\/10.1016\/j.jaci.2012.01.033.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"653_CR55","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","volume":"134","author":"A Long","year":"2014","unstructured":"Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, Iribarren C, Chen H, Carrigan G, Ros\u00e9n K, Szefler SJ. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560-567.e4. https:\/\/doi.org\/10.1016\/j.jaci.2014.02.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"653_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100721","volume":"15","author":"D Bagnasco","year":"2022","unstructured":"Bagnasco D, Canevari RF, Del Giacco S, Ferrucci S, Pigatto P, Castelnuovo P, Marseglia GL, Yalcin AD, Pelaia G, Canonica GW. Omalizumab and cancer risk: current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps. World Allergy Organ J. 2022;15(12): 100721. https:\/\/doi.org\/10.1016\/j.waojou.2022.100721.","journal-title":"World Allergy Organ J"},{"issue":"4","key":"653_CR57","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/bjd.20941","volume":"186","author":"Z Ali","year":"2022","unstructured":"Ali Z, Egeberg A, Thyssen JP, S\u00f8rensen JA, Vestergaard C, Thomsen SF. No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study. Br J Dermatol. 2022;186(4):746\u20138. https:\/\/doi.org\/10.1111\/bjd.20941.","journal-title":"Br J Dermatol"},{"issue":"1","key":"653_CR58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jaci.2014.09.017","volume":"135","author":"J Li","year":"2015","unstructured":"Li J, Goulding M, Seymour S, Starke P. EXCELS study results do not rule out potential cancer risk with omalizumab. J Allergy Clin Immunol. 2015;135(1):289. https:\/\/doi.org\/10.1016\/j.jaci.2014.09.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"653_CR59","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","volume":"139","author":"C Iribarren","year":"2017","unstructured":"Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139(5):1489-1495.e5. https:\/\/doi.org\/10.1016\/j.jaci.2016.07.038.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"653_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/2324709617724176","volume":"5","author":"S Narukonda","year":"2017","unstructured":"Narukonda S, Vinod NR, Joshi M. A case of pulmonary vein thrombosis associated with treatment of omalizumab. J Investig Med High Impact Case Rep. 2017;5(3): 2324709617724176. https:\/\/doi.org\/10.1177\/2324709617724176.","journal-title":"J Investig Med High Impact Case Rep."},{"key":"653_CR61","doi-asserted-by":"publisher","unstructured":"Oblitas CM, Galeano-Valle F, Vela-De La Cruz L, Del Toro-Cervera J, Demelo-Rodr\u00edguez P. Omalizumab as a provoking factor for venous thromboembolism. Drug Target Insights. 2019;13:1177392819861987. https:\/\/doi.org\/10.1177\/1177392819861987.","DOI":"10.1177\/1177392819861987"},{"issue":"3","key":"653_CR62","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.annder.2021.02.003","volume":"148","author":"J Beaziz","year":"2021","unstructured":"Beaziz J, Bouaziz JD, Jachiet M, Fite C, Lons-Danic D. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. Ann Dermatol Venereol. 2021;148(3):198\u2013201. https:\/\/doi.org\/10.1016\/j.annder.2021.02.003.","journal-title":"Ann Dermatol Venereol"},{"key":"653_CR63","doi-asserted-by":"publisher","unstructured":"Sachdeva M, Witol A, Mufti A, Maliyar K, Yeung J. Alopecia areata related paradoxical reactions in patients on dupilumab therapy: a systematic review. J Cutan Med Surg. 2021;25(4):451\u20132. https:\/\/doi.org\/10.1177\/1203475421995186 (Erratum in: J Cutan Med Surg. 2021;12034754211011779).","DOI":"10.1177\/1203475421995186"},{"issue":"7","key":"653_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270906","volume":"17","author":"S Park","year":"2022","unstructured":"Park S, Park SH, Byun YJ, Choi SA. Short communication: Comments on hair disorders associated with dupilumab based on VigiBase. PLoS\u00a0One. 2022;17(7): e0270906. https:\/\/doi.org\/10.1371\/journal.pone.0270906.","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"653_CR65","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjd.16711","volume":"179","author":"AS Darrigade","year":"2018","unstructured":"Darrigade AS, Legrand A, Andreu N, Jacquemin C, Boniface K, Ta\u00efeb A, Seneschal J. Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol. 2018;179(2):534\u20136. https:\/\/doi.org\/10.1111\/bjd.16711.","journal-title":"Br J Dermatol"},{"issue":"2","key":"653_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-233161","volume":"13","author":"R Nixon","year":"2020","unstructured":"Nixon R, Despiney R, Pfeffer P. Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma. BMJ Case Rep. 2020;13(2): e233161. https:\/\/doi.org\/10.1136\/bcr-2019-233161.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"653_CR67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1081-1206(10)60343-2","volume":"102","author":"FO Seeborg","year":"2009","unstructured":"Seeborg FO, Rihal PS, Czelusta A, Sanchez R, Hanson IC. Lichen planus associated with omalizumab administration in an adult with allergic asthma. Ann Allergy Asthma Immunol. 2009;102(4):349\u201351. https:\/\/doi.org\/10.1016\/S1081-1206(10)60343-2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"653_CR68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1155\/2015\/265734","volume":"22","author":"S Yung","year":"2015","unstructured":"Yung S, Han D, Lee JK. Cutaneous sarcoidosis in a patient with severe asthma treated with omalizumab. Can Respir J. 2015;22(6):315\u20136. https:\/\/doi.org\/10.1155\/2015\/265734.","journal-title":"Can Respir J"},{"issue":"1","key":"653_CR69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.annder.2020.09.577","volume":"148","author":"MA Mangin","year":"2021","unstructured":"Mangin MA, Lienhart A, Gouraud A, Roux S, Hodique F, Jouen F, Balme B, Dalle S, Debarbieux S. Onset of acquired haemophilia A after omalizumab treatment in severe bullous pemphigoid\u2014a report on two cases successfully treated with mycophenolate mofetil. Ann Dermatol Venereol. 2021;148(1):57\u20139. https:\/\/doi.org\/10.1016\/j.annder.2020.09.577.","journal-title":"Ann Dermatol Venereol"},{"issue":"9","key":"653_CR70","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1016\/j.jaip.2021.05.027","volume":"9","author":"Y To","year":"2021","unstructured":"To Y, Kono Y, Tsuzuki R, Kaneko H, To M. Rheumatoid arthritis-like polyarthralgia after the initiation of omalizumab treatment: a case series. J Allergy Clin Immunol Pract. 2021;9(9):3510\u20132. https:\/\/doi.org\/10.1016\/j.jaip.2021.05.027.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"653_CR71","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000527918","volume":"14","author":"L Kern","year":"2022","unstructured":"Kern L, Kleinheinrich L, Feldmann R, Sator P, Stella A, Breier F. Dupilumab-induced lichen planus: a case with oral and cutaneous eruptions. Case Rep Dermatol. 2022;14(3):356\u201361. https:\/\/doi.org\/10.1159\/000527918.","journal-title":"Case Rep Dermatol"},{"issue":"2","key":"653_CR72","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1378\/chest.08-2990","volume":"136","author":"ME Wechsler","year":"2009","unstructured":"Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-strauss syndrome in patients treated with omalizumab. Chest. 2009;136(2):507\u201318. https:\/\/doi.org\/10.1378\/chest.08-2990.","journal-title":"Chest"},{"issue":"2","key":"653_CR73","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1093\/rheumatology\/keaa572","volume":"60","author":"M Caminati","year":"2021","unstructured":"Caminati M, Maule M, Nalin F, Senna G, Lunardi C. Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma. Rheumatology. 2021;60(2):e59\u201360. https:\/\/doi.org\/10.1093\/rheumatology\/keaa572.","journal-title":"Rheumatology"},{"issue":"7","key":"653_CR74","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/17476348.2022.2090342","volume":"16","author":"M Caminati","year":"2022","unstructured":"Caminati M, Olivieri B, Dama A, Micheletto C, Paggiaro P, Pinter P, Senna G, Schiappoli M. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med. 2022;16(7):713\u201321. https:\/\/doi.org\/10.1080\/17476348.2022.2090342.","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"653_CR75","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/bdra.20651","volume":"88","author":"L Blais","year":"2010","unstructured":"Blais L, Kettani FZ, Elftouh N, Forget A. Effect of maternal asthma on the risk of specific congenital malformations: a population-based cohort study. Birth Defects Res A Clin Mol Teratol. 2010;88(4):216\u201322. https:\/\/doi.org\/10.1002\/bdra.20651.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"653_CR76","doi-asserted-by":"publisher","unstructured":"National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol. 2005;115(1):34\u201346. https:\/\/doi.org\/10.1016\/j.jaci.2004.10.023 (Erratum in: J Allergy Clin Immunol. 2005 Mar;115(3):477).","DOI":"10.1016\/j.jaci.2004.10.023"},{"issue":"2","key":"653_CR77","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","volume":"135","author":"J Namazy","year":"2015","unstructured":"Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H, Carrigan G, Wang Y, Veith J, Andrews EB. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407\u201312. https:\/\/doi.org\/10.1016\/j.jaci.2014.08.025.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"653_CR78","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jaci.2015.10.032","volume":"137","author":"HJ Kwon","year":"2016","unstructured":"Kwon HJ, Bang DW, Kim EN, Wi CI, Yawn BP, Wollan PC, Lahr BD, Ryu E, Juhn YJ. Asthma as a risk factor for zoster in adults: a population-based case-control study. J Allergy Clin Immunol. 2016;137(5):1406\u201312. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"653_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.718","volume":"10","author":"AB Shrestha","year":"2022","unstructured":"Shrestha AB, Umar TP, Mohammed YA, Aryal M, Shrestha S, Sapkota UH, Adhikari L, Shrestha S. Association of asthma and herpes zoster, the role of vaccination: a literature review. Immun Inflamm Dis. 2022;10(11): e718. https:\/\/doi.org\/10.1002\/iid3.718.","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"653_CR80","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12931-022-02305-1","volume":"24","author":"E Safonova","year":"2023","unstructured":"Safonova E, Yawn BP, Welte T, Wang C. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated? Respir Res. 2023;24(1):35. https:\/\/doi.org\/10.1186\/s12931-022-02305-1.","journal-title":"Respir Res"},{"issue":"1","key":"653_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100737","volume":"16","author":"AN Sitek","year":"2023","unstructured":"Sitek AN, Li JT, Pongdee T. Risks and safety of biologics: a practical guide for allergists. World Allergy Organ J. 2023;16(1): 100737. https:\/\/doi.org\/10.1016\/j.waojou.2022.100737.","journal-title":"World Allergy Organ J"},{"key":"653_CR82","doi-asserted-by":"publisher","unstructured":"Canonica GW, Blasi F, Paggiaro P, Senna G, Passalacqua G, Spanevello A, Aliberti S, Bagnasco D, Bonavia M, Bonini M, Brussino L, Bucca C, Caiaffa MF, Calabrese C, Camiciottoli G, Caminati M, Carpagnano GE, Caruso C, Centanni S, Conte ME, Corsico AG, Cosmi L, Costantino MT, Crimi N, D'Al\u00f2 S, D'Amato M, Del Giacco S, Farsi A, Favero E, Foschino Barbaro MP, Guarnieri G, Guida G, Latorre M, Lo Cicero S, Lombardi C, Macchia L, Mazza F, Menzella F, Milanese M, Montagni M, Montuschi P, Nucera E, Parente R, Patella V, Pelaia G, Pini L, Puggioni F, Ricciardi L, Ricciardolo FLM, Richeldi L, Ridolo E, Rolla G, Santus P, Scichilone N, Spadaro G, Vianello A, Viviano V, Yacoub MR, Zappa MC, Heffler E; SANI (Severe Asthma Network Italy). Oral CorticoSteroid sparing with biologics in severe asthma: a remark of the Severe Asthma Network in Italy (SANI). World Allergy Organ J. 2020;13(10):100464. https:\/\/doi.org\/10.1016\/j.waojou.2020.100464.","DOI":"10.1016\/j.waojou.2020.100464"},{"issue":"7","key":"653_CR83","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1016\/j.jaip.2020.04.006","volume":"8","author":"A Ho\u010devar","year":"2020","unstructured":"Ho\u010devar A, Kopa\u010d P, Rotar \u017d, Novljan MP, \u0160krgat S. Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab. J Allergy Clin Immunol Pract. 2020;8(7):2448\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2020.04.006.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"653_CR84","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s12026-022-09317-5","volume":"70","author":"J Holubar","year":"2022","unstructured":"Holubar J, Arnaud E, Broner J, Pers YM, Proust A, Goulabchand R. New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors. Immunol Res. 2022;70(6):721\u20134. https:\/\/doi.org\/10.1007\/s12026-022-09317-5.","journal-title":"Immunol Res"},{"issue":"4","key":"653_CR85","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","volume":"84","author":"Y Wang","year":"2021","unstructured":"Wang Y, Jorizzo JL. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration. J Am Acad Dermatol. 2021;84(4):1010\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"653_CR86","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003.","journal-title":"Drug Saf"},{"key":"653_CR87","doi-asserted-by":"publisher","unstructured":"Bergvall T, Nor\u00e9n GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65\u201377. https:\/\/doi.org\/10.1007\/s40264-013-0131-x (Erratum in: Drug Saf. 2019 Mar 12).","DOI":"10.1007\/s40264-013-0131-x"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00653-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T13:12:53Z","timestamp":1714223573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00653-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00653-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"1 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Verona within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gianluca Trifir\u00f2 has served on advisory boards\/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead and Amgen in the past three years; he was the scientific director of a Master\u2019s program on pharmacovigilance, pharmacoepidemiology and real-world evidence which has received non-conditional grants from various pharmaceutical companies; he coordinated a pharmacoepidemiology team at the University of Messina until October 2020, which has received funding for conducting observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daichii Sankyo, PTC Pharmaceuticals). He is also scientific coordinator of the academic spin-off \u2018INSPIRE srl\u2019 which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.). None of the above-mentioned activities are related to the topic of the manuscript. The other authors have no conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"VigiBase, the WHO global database of ICSRs, is the source of our information. The information comes from a variety of sources, and the probability that the suspected adverse event is drug-related is not the same in all cases; the information does not represent the opinion of the UMC or WHO.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"UMC statement"}},{"value":"The datasets generated and\/or analyzed in the current study are available in the VigiBase repository. The data presented in this study are obtainable on request from the corresponding author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed equally to this work. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}